Revisiting the 1976 "swine flu" vaccine clinical trials: Cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice

Clinical Infectious Diseases

Volumn 53, Issue 12, 2011, Pages 1179-1187

  Xie, Hang ^a   Li, Xing ^a   Gao, Jin ^a   Lin, Zhengshi ^a   Jing, Xianghong ^a   Plant, Ewan ^a   Zoueva, Olga ^a   Eichelberger, Maryna C ^a   Ye, Zhiping ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; SIALIDASE; SWINE INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CROSS REACTION; FEMALE; MOUSE; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; SURVIVAL RATE; SWINE INFLUENZA;

ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; CROSS REACTIONS; DISEASE MODELS, ANIMAL; HEMAGGLUTININS; HUMANS; IMMUNIZATION, PASSIVE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEURAMINIDASE; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; UNITED STATES;

EID: 81855173722     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir693     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:521-4.
2. Armstrong GL, Brammer L, Finelli L. Timely assessment of the severity of the 2009H1N1 influenza pandemic. Clin Infect Dis 2011; 52(Suppl 1): S83-9.
3. McCullers JA, Van De Velde LA, Allison KJ, Branum KC, Webby RJ, Flynn PM. Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis 2010; 50:1487-92.
4. Sencer DJ, Milar JD. Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis 2006; 12:29-33. (Pubitemid 43143531)
5. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 2000; 97:6108-13. (Pubitemid 30367531)
6. Sandbulte MR, Gao J, Straight TM, Eichelberger MC. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respi Viruses 2009; 3:233-40.
7. Dolin R, Wise TG, Mazur MH, Tuazon CU, Ennis FA. Immunogenicity and reactogenicity of influenza A/New Jersey/76 virus vaccines in normal adults. J Infect Dis 1977; 136(Suppl):S435-42. (Pubitemid 8293885)
8. Wise TG, Dolin R, Mazur MH, Ennis FA. Serologic responses after two sequential doses of influenza A/New Jersey/76 virus vaccine in normal young adults. J Infect Dis 1977; 136(Suppl):S496-9. (Pubitemid 8293895)
9. Wise TG, Dolin R, Mazur MH, Top FH Jr, Edelman R, Ennis FA. Serologic responses and systemic reactions in adults after vaccination with bivalent A/Victoria/75-A/New Jersey/76 and monovalent B/Hong Kong/72 influenza vaccines. J Infect Dis 1977; 136(Suppl): S507-17. (Pubitemid 8293897)
10. Kendal AP, Pereira MS, Skehel JJ. Hemagglutination inhibition. In: Kendal AP, Pereira MS, Skehel JJ, eds. Concepts and procedures for laboratory-based influenza surveillance. Atlanta, GA: Centers for Disease Control and Prevention, 1982; B17-35.
11. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43. (Pubitemid 29140593)
12. Lambre CR, Terzidis H, Greffard A, Webster RG. Measurement of antiinfluenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 1990; 135:49-57.
13. Cate TR, Rayford Y, Nino D, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010; 28:2076-9.
14. Leung GM, Nicoll A. Reflections on pandemic (H1N1) 2009 and the international response. PLoS Med 2010; 7:e1000346.
15. Parkman PD, Hopps HE, Rastogi SC, Meyer HM Jr. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 1977; 136(Suppl):S722-30. (Pubitemid 8286955)
16. Foy HM, Cooney MK, Taylor J, et al. Antibody response to influenza A/New Jersey and A/Victoria virus vaccines in 1976 and subsequent antibody levels after influenza A epidemics, 1977-1979. J Infect Dis 1980; 142:139-44.
17. Van der Vliet D, Pepin S, Lambert M, et al. Similar immunogenicity and safety of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine. Hum Vaccin 2010; 6:823-8.
18. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-52.
19. Xie H, Jing X, Li X, et al. Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS One 2011; 6:e16650.
20. Webster RG, Laver WG. Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. J lmmunol 1967; 99:49-55.
21. Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 1968; 2:778-86.
22. Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973; 1:623-5.
23. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 1974; 129:411-20.
24. Kendal AP, Noble GR, Dowdle WR. Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. J Infect Dis 1977; 136(Suppl):S415-24. (Pubitemid 8293882)
25. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4:e59.
26. Marcelin G, Bland HM, Negovetich NJ, et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J Infect Dis 2010; 202:1634-8.
27. Kilbourne ED, Laver WG, Schulman JL, Webster RG. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 1968; 2:281-8.
28. Murphy BR, Kasel JA, Chanock RM. Association of serum antineuraminidase antibody with resistance to influenza in man. N Engl J Med 1972; 286:1329-32.
29. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:69-75. (Pubitemid 9096975)
30. Fox JP, Hall CE, Cooney MK, Foy HM. Influenza virus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol 1982; 116:212-27. (Pubitemid 12048403)
31. Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 2010; 285:28403-9.